These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 31665941)

  • 1. The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib.
    Wilding CP; Elms ML; Judson I; Tan AC; Jones RL; Huang PH
    Expert Rev Anticancer Ther; 2019 Nov; 19(11):971-991. PubMed ID: 31665941
    [No Abstract]   [Full Text] [Related]  

  • 2. How we use pazopanib in treating soft-tissue sarcoma: experience at our multidisciplinary sarcoma centers.
    Van Tine BA; Trent JC
    Curr Med Res Opin; 2019 Apr; 35(4):623-629. PubMed ID: 30652922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Predictive Biomarkers of the Response to Pazopanib Based on an Integrative Analysis of High-grade Soft-tissue Sarcomas: Analysis of a Tumor Sample from a Responder and Patients with Other Soft-tissue Sarcomas.
    Suehara Y; Kohsaka S; Yamaguchi S; Hayashi T; Kurihara T; Sano K; Sasa K; Akaike K; Ueno T; Kojima S; Ikegami M; Mizuno S; Okubo T; Kim Y; Kaneko K; Saito T; Kato S; Mano H
    Clin Orthop Relat Res; 2020 Nov; 478(11):2461-2476. PubMed ID: 32567826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of pazopanib as a second-line treatment and beyond for soft tissue sarcomas: A real-life tertiary-center experience in the MENA region.
    Halim NA; Sayed RE; Alameh IA; Khoury J; Nakib CE; Zerdan MB; Charafeddine M; Farhat F; Karak FE; Assi HI
    Cancer Treat Res Commun; 2021; 26():100275. PubMed ID: 33340905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: a new treatment for metastatic soft tissue sarcoma.
    Ranieri G; Mammì M; Donato Di Paola E; Russo E; Gallelli L; Citraro R; Gadaleta CD; Marech I; Ammendola M; De Sarro G
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):322-9. PubMed ID: 24041629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas.
    Sethi TK; Keedy VL
    Curr Treat Options Oncol; 2016 Feb; 17(2):11. PubMed ID: 26931561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.
    Chamberlain FE; Wilding C; Jones RL; Huang P
    Expert Opin Investig Drugs; 2019 Jun; 28(6):505-511. PubMed ID: 31010343
    [No Abstract]   [Full Text] [Related]  

  • 8. Pazopanib in the treatment of soft tissue sarcoma.
    Schöffski P
    Expert Rev Anticancer Ther; 2012 Jun; 12(6):711-23. PubMed ID: 22716487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer.
    Koehler VF; Berg E; Adam P; Weber GL; Pfestroff A; Luster M; Kutsch JM; Lapa C; Sandner B; Rayes N; Fuss CT; Kreissl MC; Hoster E; Allelein S; Schott M; Todica A; Fassnacht M; Kroiss M; Spitzweg C
    Thyroid; 2021 Oct; 31(10):1531-1541. PubMed ID: 34405734
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series.
    Yoo KH; Kim HS; Lee SJ; Park SH; Kim SJ; Kim SH; La Choi Y; Shin KH; Cho YJ; Lee J; Rha SY
    BMC Cancer; 2015 Mar; 15():154. PubMed ID: 25885855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study.
    Oh CR; Hong JY; Kim JH; Lee JS; Kim HS; Kim TW; Ahn JH; Kim JE
    Target Oncol; 2020 Aug; 15(4):485-493. PubMed ID: 32607656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.
    Boudou-Rouquette P; Tlemsani C; Blanchet B; Huillard O; Jouinot A; Arrondeau J; Thomas-Schoemann A; Vidal M; Alexandre J; Goldwasser F
    Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1433-1444. PubMed ID: 27556889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapy and promising novel agents for the treatment of advanced soft tissue sarcomas.
    Mohindra N; Agulnik M
    Expert Opin Investig Drugs; 2015; 24(11):1409-18. PubMed ID: 26289790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic drug evaluation of pazopanib for the treatment of uterine leiomyosarcomas.
    Ferrero S; Leone Roberti Maggiore U; Aiello N; Barra F; Ditto A; Bogani G; Raspagliesi F; Lorusso D
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):881-889. PubMed ID: 28678537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma.
    Canter RJ; Ames E; Mac S; Grossenbacher SK; Chen M; Li CS; Borys D; Smith RC; Tellez J; Sayers TJ; Monjazeb AM; Murphy WJ
    BMC Cancer; 2014 Oct; 14():756. PubMed ID: 25301268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pazopanib: a promising new agent in the treatment of soft tissue sarcomas.
    Kasper B; Hohenberger P
    Future Oncol; 2011 Dec; 7(12):1373-83. PubMed ID: 22112314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072.
    Benson C; Ray-Coquard I; Sleijfer S; Litière S; Blay JY; Le Cesne A; Papai Z; Judson I; Schöffski P; Chawla S; Gil T; Piperno-Neumann S; Marréaud S; Dewji MR; van der Graaf WTA
    Gynecol Oncol; 2016 Jul; 142(1):89-94. PubMed ID: 27012429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study.
    Koca S; Beşiroğlu M; Özçelik M; Karaca M; Bilici M; Hacıoğlu B; Doğu GG; Kaplan NB; Oruç Z; Aydın D; Dane F
    J Oncol Pharm Pract; 2021 Apr; 27(3):541-546. PubMed ID: 32419618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pazopanib-induced fatal heart failure in a patient with unresectable soft tissue sarcoma and review of literature.
    Karaağaç M; Eryılmaz MK
    J Oncol Pharm Pract; 2020 Apr; 26(3):768-774. PubMed ID: 31547750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas.
    Munhoz RR; D'Angelo SP; Gounder MM; Keohan ML; Chi P; Carvajal RD; Singer S; Crago AM; Landa J; Healey JH; Qin LX; Hameed M; Ezeoke MO; Singh AS; Agulnik M; Chmielowski B; Luke JJ; Van Tine BA; Schwartz GK; Tap WD; Dickson MA
    Oncologist; 2015 Nov; 20(11):1245-6. PubMed ID: 26449382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.